Pharmaron Beijing Co., Ltd. (SHE:300759)

China flag China · Delayed Price · Currency is CNY
26.43
+0.84 (3.28%)
At close: Mar 27, 2026
Market Cap44.81B +3.6%
Revenue (ttm)13.54B +14.8%
Net Income1.51B -19.7%
EPS0.86 -19.4%
Shares Out1.83B
PE Ratio30.87
Forward PE24.25
Dividend0.20 (0.76%)
Ex-Dividend DateJul 4, 2025
Volume25,450,750
Average Volume21,918,017
Open25.26
Previous Close25.59
Day's Range25.26 - 26.55
52-Week Range20.47 - 37.63
Beta0.99
RSI42.14
Earnings DateMar 30, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotide... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 22,908
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300759
Full Company Profile

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial Statements